secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004231
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum reports $76M total rev in 2022; LIVMARLI net sales $74M; CFO Clements to step down
--------------------------------------------------------------------------------

- Total revenue $76M, LIVMARLI net product sales $74M for full year 2022 (preliminary unaudited).
- Q4 2022 product sales $27M including $5M international partner orders.
- CFO Ian Clements to step down effective May 15, 2023; will serve as consultant for 12 months.
- sNDA for LIVMARLI in PFIC on track for Q1 2023; multiple pipeline catalysts in 2023.
- Cash and investments ~$252M as of Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/d380757d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer